Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease

David L. Hemsell, Bertis B. Little, Sebastian Faro, Richard L Sweet, William J. Ledger, Alan S. Berkeley, David A. Eschenbach, Pal Wölner-Hanssen, Joseph G. Pastorek

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

This six-center, prospective, open-label clinical trial compared the efficacy and safety of three regimens recommended by the Centers for Disease Control and Prevention (CDC) for the treatment of women hospitalized for acute pelvic inflammatory disease (PID). The study focused on the response to inpatient therapy, not on long-term prevention of sequelae. A severity score was used for objective comparison of the degree of illness before and after therapy. Women were randomly assigned (in a 1:1:1 ratio) to treatment with cefoxitin plus doxycycline, clindamycin plus gentamicin, or cefotetan plus doxycycline. Two hundred seventy-five (94.2%) of 292 evaluable women required no alteration in therapeutic regimen. The three regimens produced almost identical cure rates. No serious adverse clinical or laboratory events were observed. In short, the three regimens recommended by the CDC for inpatient therapy of acute PID were similarly effective and safe.

Original languageEnglish (US)
Pages (from-to)720-727
Number of pages8
JournalClinical Infectious Diseases
Volume19
Issue number4
StatePublished - Oct 1994

Fingerprint

Pelvic Inflammatory Disease
Centers for Disease Control and Prevention (U.S.)
Doxycycline
Inpatients
Therapeutics
Cefotetan
Cefoxitin
Clindamycin
Gentamicins
Clinical Trials
Safety

ASJC Scopus subject areas

  • Immunology

Cite this

Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. / Hemsell, David L.; Little, Bertis B.; Faro, Sebastian; Sweet, Richard L; Ledger, William J.; Berkeley, Alan S.; Eschenbach, David A.; Wölner-Hanssen, Pal; Pastorek, Joseph G.

In: Clinical Infectious Diseases, Vol. 19, No. 4, 10.1994, p. 720-727.

Research output: Contribution to journalArticle

Hemsell, DL, Little, BB, Faro, S, Sweet, RL, Ledger, WJ, Berkeley, AS, Eschenbach, DA, Wölner-Hanssen, P & Pastorek, JG 1994, 'Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease', Clinical Infectious Diseases, vol. 19, no. 4, pp. 720-727.
Hemsell, David L. ; Little, Bertis B. ; Faro, Sebastian ; Sweet, Richard L ; Ledger, William J. ; Berkeley, Alan S. ; Eschenbach, David A. ; Wölner-Hanssen, Pal ; Pastorek, Joseph G. / Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. In: Clinical Infectious Diseases. 1994 ; Vol. 19, No. 4. pp. 720-727.
@article{dc5572d8890f4732b808792fe51f2db2,
title = "Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease",
abstract = "This six-center, prospective, open-label clinical trial compared the efficacy and safety of three regimens recommended by the Centers for Disease Control and Prevention (CDC) for the treatment of women hospitalized for acute pelvic inflammatory disease (PID). The study focused on the response to inpatient therapy, not on long-term prevention of sequelae. A severity score was used for objective comparison of the degree of illness before and after therapy. Women were randomly assigned (in a 1:1:1 ratio) to treatment with cefoxitin plus doxycycline, clindamycin plus gentamicin, or cefotetan plus doxycycline. Two hundred seventy-five (94.2{\%}) of 292 evaluable women required no alteration in therapeutic regimen. The three regimens produced almost identical cure rates. No serious adverse clinical or laboratory events were observed. In short, the three regimens recommended by the CDC for inpatient therapy of acute PID were similarly effective and safe.",
author = "Hemsell, {David L.} and Little, {Bertis B.} and Sebastian Faro and Sweet, {Richard L} and Ledger, {William J.} and Berkeley, {Alan S.} and Eschenbach, {David A.} and Pal W{\"o}lner-Hanssen and Pastorek, {Joseph G.}",
year = "1994",
month = "10",
language = "English (US)",
volume = "19",
pages = "720--727",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease

AU - Hemsell, David L.

AU - Little, Bertis B.

AU - Faro, Sebastian

AU - Sweet, Richard L

AU - Ledger, William J.

AU - Berkeley, Alan S.

AU - Eschenbach, David A.

AU - Wölner-Hanssen, Pal

AU - Pastorek, Joseph G.

PY - 1994/10

Y1 - 1994/10

N2 - This six-center, prospective, open-label clinical trial compared the efficacy and safety of three regimens recommended by the Centers for Disease Control and Prevention (CDC) for the treatment of women hospitalized for acute pelvic inflammatory disease (PID). The study focused on the response to inpatient therapy, not on long-term prevention of sequelae. A severity score was used for objective comparison of the degree of illness before and after therapy. Women were randomly assigned (in a 1:1:1 ratio) to treatment with cefoxitin plus doxycycline, clindamycin plus gentamicin, or cefotetan plus doxycycline. Two hundred seventy-five (94.2%) of 292 evaluable women required no alteration in therapeutic regimen. The three regimens produced almost identical cure rates. No serious adverse clinical or laboratory events were observed. In short, the three regimens recommended by the CDC for inpatient therapy of acute PID were similarly effective and safe.

AB - This six-center, prospective, open-label clinical trial compared the efficacy and safety of three regimens recommended by the Centers for Disease Control and Prevention (CDC) for the treatment of women hospitalized for acute pelvic inflammatory disease (PID). The study focused on the response to inpatient therapy, not on long-term prevention of sequelae. A severity score was used for objective comparison of the degree of illness before and after therapy. Women were randomly assigned (in a 1:1:1 ratio) to treatment with cefoxitin plus doxycycline, clindamycin plus gentamicin, or cefotetan plus doxycycline. Two hundred seventy-five (94.2%) of 292 evaluable women required no alteration in therapeutic regimen. The three regimens produced almost identical cure rates. No serious adverse clinical or laboratory events were observed. In short, the three regimens recommended by the CDC for inpatient therapy of acute PID were similarly effective and safe.

UR - http://www.scopus.com/inward/record.url?scp=0028047941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028047941&partnerID=8YFLogxK

M3 - Article

C2 - 7803638

AN - SCOPUS:0028047941

VL - 19

SP - 720

EP - 727

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -